These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 1569651)

  • 41. Physicochemical action of potassium-magnesium citrate in nephrolithiasis.
    Pak CY; Koenig K; Khan R; Haynes S; Padalino P
    J Bone Miner Res; 1992 Mar; 7(3):281-5. PubMed ID: 1585829
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Noncitrus alkaline fruit: a dietary alternative for the treatment of hypocitraturic stone formers.
    Baia Lda C; Baxmann AC; Moreira SR; Holmes RP; Heilberg IP
    J Endourol; 2012 Sep; 26(9):1221-6. PubMed ID: 22500592
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Renal tubular cell damage and oxidative stress in renal stone patients and the effect of potassium citrate treatment.
    Tungsanga K; Sriboonlue P; Futrakul P; Yachantha C; Tosukhowong P
    Urol Res; 2005 Feb; 33(1):65-9. PubMed ID: 15565439
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Seasonal changes in serum and erythrocyte potassium among renal stone formers from northeastern Thailand.
    Sriboonlue P; Tungsanga K; Tosukhowong P; Sitprija V
    Southeast Asian J Trop Med Public Health; 1993 Jun; 24(2):287-92. PubMed ID: 8266231
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of orange juice consumption on urinary stone risk factors.
    Wabner CL; Pak CY
    J Urol; 1993 Jun; 149(6):1405-8. PubMed ID: 8501777
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The lack of influence of long-term potassium citrate and calcium citrate treatment in total body aluminum burden in patients with functioning kidneys.
    Sakhaee K; Ruml L; Padalino P; Haynes S; Pak CY
    J Am Coll Nutr; 1996 Feb; 15(1):102-6. PubMed ID: 8632109
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Risk factors for low urinary citrate in calcium nephrolithiasis: low vegetable fibre intake and low urine volume to be added to the list.
    Hess B; Michel R; Takkinen R; Ackermann D; Jaeger P
    Nephrol Dial Transplant; 1994; 9(6):642-9. PubMed ID: 7970090
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Enhanced calcium bioavailability from a solubilized form of calcium citrate.
    Pak CY; Harvey JA; Hsu MC
    J Clin Endocrinol Metab; 1987 Oct; 65(4):801-5. PubMed ID: 3654922
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Renal excretion of citrate in patients with chronic renal failure or nephrolithiasis.
    Chen SM; Chung LC; Lee YH; Young TK
    J Formos Med Assoc; 1991 Jan; 90(1):41-7. PubMed ID: 1679108
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Changes in urinary stone risk factors in hypocitraturic calcium oxalate stone formers treated with dietary sodium supplementation.
    Stoller ML; Chi T; Eisner BH; Shami G; Gentle DL
    J Urol; 2009 Mar; 181(3):1140-4. PubMed ID: 19152919
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Calcium citrate without aluminum antacids does not cause aluminum retention in patients with functioning kidneys.
    Sakhaee K; Wabner CL; Zerwekh JE; Copley JB; Pak L; Poindexter JR; Pak CY
    Bone Miner; 1993 Jan; 20(1):87-97. PubMed ID: 8453325
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Citrate and mineral metabolism: kidney stones and bone disease.
    Caudarella R; Vescini F; Buffa A; Stefoni S
    Front Biosci; 2003 Sep; 8():s1084-106. PubMed ID: 12957820
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Gouty diathesis and sarcoidosis in patient with recurrent calcium nephrolithiasis.
    Harvey JA; Pak CY
    J Urol; 1988 Jun; 139(6):1287-9. PubMed ID: 3373603
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Use of citrate in patients with nephrolithiasis].
    Marangella M
    G Ital Nefrol; 2017 Aug; 34(4):51-60. PubMed ID: 28762682
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Contributory metabolic factors in the development of nephrolithiasis in patients with medullary sponge kidney.
    Yagisawa T; Kobayashi C; Hayashi T; Yoshida A; Toma H
    Am J Kidney Dis; 2001 Jun; 37(6):1140-3. PubMed ID: 11382681
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Oxalate metabolism in renal stone disease with special reference to calcium metabolism and intestinal absorption.
    Lindsjö M
    Scand J Urol Nephrol Suppl; 1989; 119():1-53. PubMed ID: 2669121
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The effects of potassium and magnesium supplementations on urinary risk factors of renal stone patients.
    Jaipakdee S; Prasongwatana V; Premgamone A; Reungjui S; Tosukhowong P; Tungsanga K; Suwantrai S; Noppawinyoowong C; Maskasame S; Sriboonlue P
    J Med Assoc Thai; 2004 Mar; 87(3):255-63. PubMed ID: 15117041
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Superior calcium absorption from calcium citrate than calcium carbonate using external forearm counting.
    Harvey JA; Kenny P; Poindexter J; Pak CY
    J Am Coll Nutr; 1990 Dec; 9(6):583-7. PubMed ID: 2273192
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Sodium dicarboxylate cotransporter-1 expression in renal tissues and its role in rat experimental nephrolithiasis.
    He Y; Chen X; Yu Z; Wu D; Lv Y; Shi S; Zhu H
    J Nephrol; 2004; 17(1):34-42. PubMed ID: 15151257
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Modification by food of the calcium absorbability and physicochemical effects of calcium citrate.
    Wabner CL; Pak CY
    J Am Coll Nutr; 1992 Oct; 11(5):548-52. PubMed ID: 1452953
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.